



Caprion Bioscience to Present “Analytical Challenges and Strategies of Using MRM/MS-Based Methods for Biomarker Development”

**10th GTC BIO Conference, Biomarkers in Drug Discovery and Development,
Berlin, Germany, October 5-7, 2016**

Montreal, Canada – October 4, 2016— Caprion announced today that Dr. Lorella Di Donato, Senior Vice President of Scientific Operations will present data on October 5th at the 10th Annual GTC BIO Conference, “Biomarkers in Drug Discovery and Development” in Berlin, Germany. The presentation will feature three case studies addressing the analytical challenges of reproducibility, sensitivity, and quantitation. The presentation will showcase different strategies to resolve analytical challenges present in MS-based methods which allows for significant progress in the use of protein biomarkers in drug development programs. In addition, the case studies will describe the best in class methodologies for taking differentially expressed proteins from discovery to clinical practice in Alzheimer’s disease, Diabetes, and Cancer.

Martin LeBlanc, President and CEO of Caprion said, “We are excited to present these case studies highlighting Caprion’s ability to develop relevant biomarker strategies for clinical trials in a variety of disease states utilizing robust analytical methods with a MRM/MS based technology platform.”

Presentation Title: “Analytical Challenges and Strategies of Using MRM/MS-Based Methods for Biomarker Development”

Speaker: Lorella Di Donato PhD., Sr. Vice President, Scientific Operations, Caprion Biosciences

Time: October 5, 2016, 12:15 pm

Place: Abion Hotel, GTO BIO Conference, Berlin, Germany

About Caprion Bioscience

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta[®], offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta[™], offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the development and clinical measurement of protein biomarkers. Caprion also leverages ProteoCarta and Immune Carta to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With its GLP and GCLP accredited laboratories in Montreal, Canada and Gosselies, Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 60 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by GHO Capital. For more information, please visit www.caprion.com.

Media Contact

Carol Berry

Chief Business Officer, SVP

Caprion Bioscience

cberry@caprion.com

514.360.3600